22. Nov 2022 News CatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visugromab in Patients with Solid Tumors
17. Nov 2022 News FundaMental Pharma launches with EUR 10 million in Seed financing led by BGV and Thuja Capital to advance a First-in-Class neuroprotectant
29. Sep 2022 News Taking a page from the Amazon playbook, Berlin’s cross-selling specialist 35up banks another €5 million
10. Sep 2022 News CatalYm Demonstrates Clinical Efficacy and Tolerability in First-in- Human Phase 1 Trial for Visugromab and Nivolumab Combination
